This new article publication from Acta Pharmaceutica Sinica B, discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting ...
In the continuously changing environment of drug development and molecular biology, sensitive and high-throughput kinase activity monitoring remains a key component of target validation and inhibitor ...
BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results